AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo.

medsolvedynamics.com | [email protected] 

#RadiationOncology #AIinHealthcare #OncologyLeadership #HealthcareAI